A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.

@article{Wakelee2012ADR,
  title={A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.},
  author={Heather A. Wakelee and J W Lee and Nasser Hanna and Anne M. Traynor and David Paul Carbone and Joan Hoff Schiller},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2012},
  volume={7 10},
  pages={1574-82}
}
INTRODUCTION Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design. METHODS Patients received 400 mg of sorafenib orally twice daily for two cycles (2 months) (step 1). Responding patients on step 1 continued on sorafenib; progressing patients went off study, and patients with stable disease were randomized to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS